Bioorthogonal CRISPR/Cas9‐Drug Conjugate: A Combinatorial Nanomedicine Platform

Bioorthogonal CRISPR/Cas9‐Drug Conjugate: A Combinatorial Nanomedicine Platform

Abstract Bioconjugation of proteins can substantially expand the opportunities in biopharmaceutical development, however, applications are limited for the gene editing machinery despite its tremendous therapeutic potential. Here, a self‐delivered nanomedicine platform based on bioorthogonal CRISPR/C...

Full description

Bibliographic Details
Main Authors: Marcel Janis Beha, Joo‐Chan Kim, San Hae Im, Yunsu Kim, Seungju Yang, Juhee Lee, Yu Ri Nam, Haeshin Lee, Hee‐Sung Park, Hyun Jung Chung
Format: Article
Language:English
Published: Wiley 2023-09-01
Series:Advanced Science
Subjects:
bioorthogonal
cancer therapy
chemotherapeutic drugs
combinatorial delivery
CRISPR/Cas9
gene editing
Online Access:https://doi.org/10.1002/advs.202302253

Internet

https://doi.org/10.1002/advs.202302253

Similar Items